Liliana Mendonca

Dr. Liliana Mendonca

Center for Neuroscience and Cell Biology-CNC, University of Coimbra
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Biomaterials
Verified
Journal Article
Closed access
MCMariana Conceição
Mariana Conceição
Liliana MendoncaLiliana Mendonca
Liliana Mendonca
CNClévio Nóbrega
Clévio Nóbrega
Célia GomesCélia Gomes
Célia Gomes
PCPedro Costa
Pedro Costa
LALuis Pereira De Almeida
Luis Pereira De Almeida

1 January 2013 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
PDF file
PCPedro M. Costa
Pedro M. Costa
Ana Luísa CardosoAna Luísa Cardoso
Ana Luísa Cardoso
Liliana MendoncaLiliana Mendonca
Liliana Mendonca
ASAngelo Serani
Angelo Serani
CCCarlos Manuel Tavares Custódia
Carlos Manuel Tavares Custódia
MLMaria Monteiro Pedroso De Lima
Maria Monteiro Pedroso De Lima
The present work aimed at the development and application of a lipid-based nanocarrier for targeted delivery of nucleic acids to glioblastoma (GBM). For this purpose, chlorotoxin (CTX), a peptide reported to bind selectively to glioma cells while showing no affinity for non-neoplastic cells, was covalently coupled to liposomes encapsulating antisense oligonucleotides (asOs) or small interfering RNAs (siRNAs). The resulting targeted nanoparticles, designated CTX-coupled stable nucleic acid lipid particles (SNALPs), exhibited excellent features for in vivo application, namely small size (<180 nm) and neutral surface charge. Cellular association and internalization studies revealed that attachment of CTX onto the liposomal surface enhanced particle internalization into glioma cells, whereas no significant internalization was observed in noncancer cells. Moreover, nanoparticle-mediated miR-21 silencing in U87 human GBM and GL261 mouse glioma cells resulted in increased levels of the tumor suppressors PTEN and PDCD4, caspase 3/7 activation and decreased tumor cell proliferation. Preliminary in vivo studies revealed that CTX enhances particle internalization into established intracranial tumors. Overall, our results indicate that the developed targeted nanoparticles represent a valuable tool for targeted nucleic acid delivery to cancer cells. Combined with a drug-based therapy, nanoparticle-mediated miR-21 silencing constitutes a promising multimodal therapeutic approach towards GBM.

17 May 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
RMRicardo Moreira
Ricardo Moreira
CNClévio Nóbrega
Clévio Nóbrega
LALuís Pereira de Almeida
Luís Pereira de Almeida
Liliana MendoncaLiliana Mendonca
Liliana Mendonca
Neurodegenerative diseases are characterized by extensive loss of function or death of brain cells, hampering the life quality of patients. Brain-targeted drug delivery is challenging, with a low success rate this far. Therefore, the application of targeting ligands in drug vehicles, such as lipid-based and polymeric nanoparticles, holds the promise to overcome the blood-brain barrier (BBB) and direct therapies to the brain, in addition to protect their cargo from degradation and metabolization. In this review, we discuss the barriers to brain delivery and the different types of brain-targeting ligands currently in use in brain-targeted nanoparticles, such as peptides, proteins, aptamers, small molecules, and antibodies. Moreover, we present a detailed review of the different targeting ligands used to direct nanoparticles to specific brain cells, like neurons (C4-3 aptamer, neurotensin, Tet-1, RVG, and IKRG peptides), astrocytes (Aquaporin-4, D4, and Bradykinin B2 antibodies), oligodendrocytes (NG-2 antibody and the biotinylated DNA aptamer conjugated to a streptavidin core Myaptavin-3064), microglia (CD11b antibody), neural stem cells (QTRFLLH, VPTQSSG, and NFL-TBS.40–63 peptides), and to endothelial cells of the BBB (transferrin and insulin proteins, and choline). Reports demonstrated enhanced brain-targeted delivery with improved transport to the specific cell type targeted with the conjugation of these ligands to nanoparticles. Hence, this strategy allows the implementation of high-precision medicine, with reduced side effects or unwanted therapy clearance from the body. Nevertheless, the accumulation of some of these nanoparticles in peripheral organs has been reported indicating that there are still factors to be improved to achieve higher levels of brain targeting. This review is a collection of studies exploring targeting ligands for the delivery of nanoparticles to the brain and we highlight the advantages and limitations of this type of approach in precision therapies.

19 December 2014 in Brain
Verified
Journal Article
Closed access
PDF file
Liliana MendoncaLiliana Mendonca
Liliana Mendonca
CNClévio Nóbrega
Clévio Nóbrega
HHHirokazu Hirai
Hirokazu Hirai
BKBrian K. Kaspar
Brian K. Kaspar
LALuis Pereira De Almeida
Luis Pereira De Almeida
Machado-Joseph disease is a neurodegenerative disease without effective treatment. Patients with Machado-Joseph disease exhibit significant motor impairments such as gait ataxia, associated with multiple neuropathological changes including mutant ATXN3 inclusions, marked neuronal loss and atrophy of the cerebellum. Thus, an effective treatment of symptomatic patients with Machado-Joseph disease may require cell replacement, which we investigated in this study. For this purpose, we injected cerebellar neural stem cells into the cerebellum of adult Machado-Joseph disease transgenic mice and assessed the effect on the neuropathology, neuroinflammation mediators and neurotrophic factor levels and motor coordination. We found that upon transplantation into the cerebellum of adult Machado-Joseph disease mice, cerebellar neural stem cells differentiate into neurons, astrocytes and oligodendrocytes. Importantly, cerebellar neural stem cell transplantation mediated a significant and robust alleviation of the motor behaviour impairments, which correlated with preservation from Machado-Joseph disease-associated neuropathology, namely reduction of Purkinje cell loss, reduction of cellular layer shrinkage and mutant ATXN3 aggregates. Additionally, a significant reduction of neuroinflammation and an increase of neurotrophic factors levels was observed, indicating that transplantation of cerebellar neural stem cells also triggers important neuroprotective effects. Thus, cerebellar neural stem cells have the potential to be used as a cell replacement and neuroprotective approach for Machado-Joseph disease therapy. * Abbreviations : HBSS : Hank’s balanced salt solution NSC : neural stem cell

14 June 2019 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
CNClévio Nóbrega
Clévio Nóbrega
Liliana MendoncaLiliana Mendonca
Liliana Mendonca
AMAdriana Marcelo
Adriana Marcelo
ALAntonin Lamazière
Antonin Lamazière
STSandra Tomé
Sandra Tomé
SASandro Paiva Fernandes Alves
Sandro Paiva Fernandes Alves

11 December 2009 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
Liliana MendoncaLiliana Mendonca
Liliana Mendonca
FFFilipe Firmino
Filipe Firmino
João Nuno MoreiraJoão Nuno Moreira
João Nuno Moreira
MLMaria Monteiro Pedroso De Lima
Maria Monteiro Pedroso De Lima
SSSérgio Simões
Sérgio Simões